03605nam a2200313 4500 384278 9291681687 384278 20070514d2004 y0pory50 ba eng Hepatitis C and injecting drug use impacts, costs and policy options European Monitoring Centre for Drugs and Drug Addiction, EMCDDA Luxembourg Office for Official Publications of the European Communities 2004 389 p. 24 cm EMCDDA Monographs 7 Também disponível em formato pdf através de: https://www.emcdda.europa.eu/?nnodeid=428 Foreword (Georges Estievenart). General introduction (Wien Limburg; Lucas Wiessing; Johannes Jager). Part I - Natural history, treatment, quality of life, epidemiology and prevention: introduction. Chapter 1 - Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview (Wien Limburg). Chapter 2 - Recent developments in hepatitis C diagnostics and treatment (Thierry Poynard). Chapter 3 - Hepatitis C and quality of life (Graham Foster). Chapter 4 - Surveillance of hepatitis C infection among injecting drug users in the European Union (Lucas Wiessing; Kirsty Roy; David Sapinho; Gordon Hay; Avril Taylor; David Goldberg; Richard Hartnoll). Part II - Models of hepatitis C, injecting drug use and policy options: Introduction. Chapter 5 - Modelling the transmission of hepatitis C in injecting drug users (Mirjam Kretzschmar; Lucas Wiessing). Chapter 6 - Modelling injecting drug use and hepatitis C in injecting drug users (Carla Rossi; Nicolina Esposito). Chapter 7 - Modelling policy options to control problem drug use (Gernot Tragler). Part III - Healthcare costs of drug-related hepatitis C infection: introduction. Chapter 8 - Updated healthcare cost estimates for drug-related hepatitis C infections in the European Union (Maarten Postma; Lucas Wiessing and Johannes Jager). Chapter 9 - Cost-effectiveness of treatment of hepatitis C in injecting drug users (John Wong; Diana Sylvestre; Uwe Siebert). Part IV - Wider costs of drug use: introduction. Chapter 10 - Assessment of the indirect costs of injecting drug use: which methods should be employed? (Robert Welte; Hans-Helmut König; Johannes Jager; Reiner Leidl). Chapter 11 - Models to compute the costs to society of injecting drug use and related morbidity (Fernando Antoñanzas; Roberto Rodríguez; María Velasco). Chapter 12 - Assessing the tangible and intangible costs of illicit drug use. Chapter 13 - Social costs of drug use in France (Pierre Kopp; Nicolas Blanchard). Part V - Cost-effectiveness of needle and syringe programmes and methadone maintenance: introduction. Chapter 14 - Cost-effectiveness of needle and syringe programmes: a review of the literature (Ardine de Wit; Jasper Bos). Chapter 15 - The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C (Harold Pollack; Robert Heimer). General conclusions (Lucas Wiessing; Wien Limburg; Johannes Jager). Contributors. Abbreviations. PREVENÇÃO DA TOXICODEPENDÊNCIA 103892 DOENÇA INFECCIOSA 100267 POLÍTICA DE SAÚDE 234372 POLÍTICA SOCIAL 234807 POLÍTICA ORÇAMENTAL 235030 OEDT 321506 UNIÃO EUROPEIA 224774 EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION 351987 Oferta 0 PJ_19_000000000000000_D_65 2022-06-06 PJ28034 414155 PJ PJ PJ128034 PJ19.D.65 2022-06-06 0 MO Oferta